You are here

Phase 3 Results for Kogenate FS Presented at Hemophilia Meeting

Bayer Healthcare released preliminary data to the press on July 12.

A total of 84 subjects aged 12 to 50 years were randomly assigned to receive either prophylaxis with Kogenate FS (25 IU/kg three times per week) or on-demand treatment, with a planned follow-up period of 3 years.

After a median follow-up period of 1.7 years, significantly fewer bleeding events occurred per year with prophylaxis versus on-demand treatment (median, 0.0 vs. 27.9, respectively; P

Kogenate FS, antihemophilic factor (recombinant), is a recombinant factor V3 treatment indicated for the control and prevention of bleeding episodes and perioperative management in adults and children with hemophilia A. Kogenate FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no pre-existing joint damage.

Bayer submitted an application to the FDA requesting an adult prophylaxis indication for Kogenate FS on June 21.

For more information, read the news article in the Sacramento Bee.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs